U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations [Internet]. Geneva: World Health Organization; 2022.

Cover of Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations

Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations [Internet].

Show details

References

1.
Building health systems resilience for universal health coverage and health security during the COVID-19 pandemic and beyond. Geneva: World Health Organization; 2021.
2.
Early warning advisory on new psychoactive substances. United Nations Office on Drugs and Crime; 2022 (https://www​.unodc.org/LSS/Page/NPS, accessed 14 March 2022).
3.
Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations: Geneva; World Health Organization; 2016. [PubMed: 27559558]
4.
Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva: World Health Organization; 2016. Contract No: WHO/HIV/2016.06.
5.
Global health sector strategy on sexually transmitted infections, 2016–2021. Geneva: World Health Organization; 2016.
6.
Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-social context. Med Anthropol Q. 2003;17(4):423–41. [PubMed: 14716917]
7.
Maheu-Giroux M, Vesga JF, Diabaté S, Alary M, Baral S, Diouf D, et al. Changing dynamics of HIV transmission in Côte d’Ivoire: modeling who acquired and transmitted infections and estimating the impact of past HIV interventions (1976–2015). J Acquir Immune Defic Syndr. 2017;75(5):517–27. [PMC free article: PMC5508974] [PubMed: 28471837]
8.
Mukandavire C, Walker J, Schwartz S, Boily MC, Danon L, Lyons C, et al. Estimating the contribution of key populations towards the spread of HIV in Dakar, Senegal. J Int AIDS Soc. 2018;21(5):e25126. [PMC free article: PMC6055131] [PubMed: 30033604]
9.
Stone J, Mukandavire C, Boily MC, Fraser H, Mishra S, Schwartz S, et al. Estimating the contribution of key populations towards HIV transmission in South Africa. J Int AIDS Soc. 2021;24(1):e25650. [PMC free article: PMC7855076] [PubMed: 33533115]
10.
Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150–66. [PMC free article: PMC6657799] [PubMed: 30035835]
11.
Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089–102. [PubMed: 27427453]
12.
Jin F, Dore GJ, Matthews G, Luhmann N, Macdonald V, Bajis S, et al. Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(1):39–56. [PubMed: 33217341]
13.
Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393(10178):1319–29. [PMC free article: PMC6484702] [PubMed: 30704789]
14.
Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Current opinion in HIV and AIDS. 2015;10(5):374–80. [PMC free article: PMC4659815] [PubMed: 26248124]
15.
Pitcher AB, Borquez A, Skaathun B, Martin NK. Mathematical modeling of hepatitis C virus (HCV) prevention among people who inject drugs: a review of the literature and insights for elimination strategies. J Theor Biol. 2019;481:194–201. [PMC free article: PMC6522340] [PubMed: 30452959]
16.
Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9(9):Cd012021. [PMC free article: PMC5621373] [PubMed: 28922449]
17.
Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis. 2018;18(1):1–12. [PMC free article: PMC5809955] [PubMed: 29433454]
18.
Miranda NT, de Souza RL, Monteiro JC, Costa IB, Siravenha LQ, da Luz AL, et al. Seroprevalence of HBV and HCV in female sex workers from four cities in the state of Para, northern Brazil. J Med Virol. 2021;93(6):3730–7. [PubMed: 33368401]
19.
Adeyemi OA, Mitchell A, Shutt A, Crowell TA, Ndembi N, Kokogho A, et al. Hepatitis B virus infection among men who have sex with men and transgender women living with or at risk for HIV: a cross sectional study in Abuja and Lagos, Nigeria. BMC Infect Dis. 2021;21(1):1–8. [PMC free article: PMC8259010] [PubMed: 34229613]
20.
Moradi, Ghobad, Marzieh Soheili, Roya Rashti, Hojat Dehghanbanadaki, Elham Nouri, Farima Zakaryaei, Elnaz Ezzati Amini, Sheno Baiezeedi, Sanaz Ahmadi, and Yousef Moradi. “The prevalence of hepatitis C and hepatitis B in lesbian, gay, bisexual and transgender populations: a systematic review and meta-analysis.” European Journal of Medical Research 27, no. 1 (2022): 1–11. [PMC free article: PMC8962539] [PubMed: 35346371]
21.
Stockdale AJ, Kreuels B, Henrion MY, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523–32. [PMC free article: PMC7438974] [PubMed: 32335166]
22.
Migueres M, Lhomme S, Izopet J. Hepatitis A: Epidemiology, high-risk groups, prevention and research on antiviral treatment. Viruses. 2021;13(10). [PMC free article: PMC8540458] [PubMed: 34696330]
23.
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch X, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99. [PubMed: 21067372]
24.
Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(5):F12–23. [PubMed: 23199955]
25.
James C, Harfouche M, Welton NJ, Turner KM, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020;98(5):315–29. [PMC free article: PMC7265941] [PubMed: 32514197]
26.
Poteat T, White RH, Footer KHA, Park JN, Galai N, Huettner S, et al. Characterising HIV and STIs among transgender female sex workers: a longitudinal analysis. Sex Transm Infect. 2021;97(3):226–31. [PMC free article: PMC7769682] [PubMed: 32366602]
27.
McLaughlin MM, Chow EP, Wang C, Yang LG, Yang B, Huang JZ, et al. Sexually transmitted infections among heterosexual male clients of female sex workers in China: a systematic review and meta-analysis. PLoS One. 2013;8(8):e71394. [PMC free article: PMC3741140] [PubMed: 23951153]
28.
Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV Infection: a systematic review and meta-analysis. JAMA Netw open. 2019;2(12):e1917134. [PMC free article: PMC6991203] [PubMed: 31825501]
29.
Torrone EA, Morrison CS, Chen PL, Kwok C, Francis SC, Hayes RJ, et al. Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med. 2018;15(2):e1002511. [PMC free article: PMC5828349] [PubMed: 29485986]
30.
Van Gerwen OT, Jani A, Long DM, Austin EL, Musgrove K, Muzny CA. Prevalence of sexually transmitted infections and human immunodeficiency virus in transgender persons: a systematic review. Transgend Health. 2020;5(2):90–103. [PMC free article: PMC7347015] [PubMed: 32656353]
31.
Tsuboi M, Evans J, Davies EP, Rowley J, Korenromp EL, Clayton T, et al. Prevalence of syphilis among men who have sex with men: a global systematic review and meta-analysis from 2000–20. Lancet Glob Health. 2021;9(8):e1110–e8. [PMC free article: PMC9150735] [PubMed: 34246332]
32.
Dumchev K. Challenges of sexually transmitted infections and sexual health among people who inject drugs. Curr Opin Infect Dis. 2022;35(1):55–60. [PubMed: 34799511]
33.
Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Reviews. 2014;27(3):587–613. [PMC free article: PMC4135894] [PubMed: 24982323]
34.
Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol. 2008;23(7pt1):1000–8. [PubMed: 18707597]
35.
Thornton AC, Jose S, Bhagani S, Chadwick D, Dunn D, Gilson R, et al. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. AIDS. 2017;31(18):2525. [PMC free article: PMC5690308] [PubMed: 28926400]
36.
Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808. [PubMed: 26922272]
37.
Davlidova S, Haley-Johnson Z, Nyhan K, Farooq A, Vermund SH, Ali S. Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: a systematic review. Int J Infect Dis. 2021;104:510–25. [PubMed: 33385583]
38.
Cohen MS, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. Journal Int AIDS Soc. 2019;22:e25355. [PMC free article: PMC6715951] [PubMed: 31468737]
39.
Mayer, Kenneth H., and Lao-Tzu Allan-Blitz. “Similar, but different: drivers of the disproportionate HIV and sexually transmitted infection burden of key populations.” Journal of the International AIDS Society 22, no. Suppl Suppl 6 (2019). [PMC free article: PMC6716057] [PubMed: 31468653]
40.
Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017;17(12):1303–16. [PMC free article: PMC5700807] [PubMed: 28843576]
41.
Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV incidence. AIDS. 2009;23(12):1595–8. [PubMed: 19512858]
42.
Wu MY, Gong HZ, Hu KR, Zheng HY, Wan X, Li J. Effect of syphilis infection on HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect. 2021;97(7):525–33. [PMC free article: PMC8543214] [PubMed: 33219164]
43.
Massad LS, Xie X, Burk RD, D’Souza G, Darragh TM, Minkoff H, et al. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women. Am J Obstet Gynecol. 2016;214(3):354.e1–6. [PMC free article: PMC4775397] [PubMed: 26433170]
44.
Stelzle D, Tanaka LF, Lee KK, Khalil AI, Baussano I, Shah AS, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021;9(2):e161–e9. [PMC free article: PMC7815633] [PubMed: 33212031]
45.
Global AIDS Strategy 2021–2026. End Inequalities. End AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2021.
46.
Key considerations for differentiated antiretroviral therapy delivery for specific populations: children, adolescents, pregnant and breastfeeding women and key populations. Geneva: World Health Organization; 2017.
47.
Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26:S5–S11. [PubMed: 25727260]
48.
Cambiano V, Miners A, Dunn D, McCormack S, Ong KJ, Gill ON, et al. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation. Lancet Infect Dis. 2018;18(1):85–94. [PMC free article: PMC5988036] [PubMed: 29054789]
49.
Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS medicine. 2013;10(3):e1001401. [PMC free article: PMC3595225] [PubMed: 23554579]
50.
Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Pub Health. 2000;90(7):1100–11. [PMC free article: PMC1446290] [PubMed: 10897189]
51.
United Nations General Assembly. Universal Declaration of Human Rights. United Nations resolution A/RES/217A of 10 December 1948.
52.
International Guidelines on HIV/AIDS and Human Rights, (2006). Geneva: Joint United Nations Programme on HIV/AIDS; 2006.
53.
International Code of Medical Ethics, (2006). Pilanesberg: World Medical Association; 2006
54.
Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a world converging within a generation. Lancet. 2013;382(9908):1898–955. [PubMed: 24309475]
55.
The greater involvement of people living with HIV (GIPA): Policy Brief. Geneva: Joint United Nations Programme on HIV/AIDS; 2007.
56.
Handbook for guideline development, second edition. Geneva: World Health Organization; 2014.
57.
United Nations General Assembly. Universal Declaration of Human Rights. United Nations resolution A/RES/217A of 10 December 1948.
58.
United Nations General Assembly. The Vienna Declaration and Programme of Action, June 1993: with the opening statement of United Nations Secretary-General Boutros Boutros-Ghali. United Nations resolution 48/121 of 25 June 1993.
59.
United Nations General Assembly. International Covenant on Economic, Social and Cultural Rights. United Nations resolution 2200A of 1966.
60.
United Nations General Assembly. International Covenant on Civil and Political Rights. United Nations resolution 2200A of 1966.
61.
Evidence for eliminating HIV-related stigma and discrimination — guidance for countries to implement effective programmes to eliminate HIV-related stigma and discrimination in six settings. Geneva: Joint United Nations Programme on HIV/AIDS; 2020.
62.
Cichowitz C, Rubenstein L, Beyrer C. Forced anal examinations to ascertain sexual orientation and sexual behavior: an abusive and medically unsound practice. PLoS Med. 2018;15(3):e1002536. [PMC free article: PMC5856262] [PubMed: 29547659]
63.
Argento E, Goldenberg S, Shannon K. Preventing sexually transmitted and blood borne infections (STBBIs) among sex workers: a critical review of the evidence on determinants and interventions in high-income countries. BMC Infect Dis. 2019;19(1):1–19. [PMC free article: PMC6399876] [PubMed: 30832596]
64.
Baker P, Beletsky L, Avalos L, Venegas C, Rivera C, Strathdee SA, et al. Policing practices and risk of HIV infection among people who inject drugs. Epidemiol Rev. 2020;42(1):27–40. [PMC free article: PMC7879596] [PubMed: 33184637]
65.
Bakko M, Kattari SK. Transgender-related insurance denials as barriers to transgender healthcare: differences in experience by insurance type. J Gen Intern Med. 2020;35(6):1693–700. [PMC free article: PMC7280420] [PubMed: 32128693]
66.
DeBeck K, Cheng T, Montaner JS, Beyrer C, Elliott R, Sherman S, et al. HIV and the criminalisation of drug use among people who inject drugs: a systematic review. Lancet HIV. 2017;4(8):e357–e74. [PMC free article: PMC6005363] [PubMed: 28515014]
67.
Hill BJ, Crosby R, Bouris A, Brown R, Bak T, Rosentel K, et al. Exploring transgender legal name change as a potential structural intervention for mitigating social determinants of health among transgender women of color. Sex Res Social Policy. 2018;15(1):25–33. [PMC free article: PMC5837073] [PubMed: 29520314]
68.
Lyons CE, Schwartz SR, Murray SM, Shannon K, Diouf D, Mothopeng T, et al. The role of sex work laws and stigmas in increasing HIV risks among sex workers. Nat Commun. 2020;11(1):1–10. [PMC free article: PMC7028952] [PubMed: 32071298]
69.
Millett GA, Jeffries WL, Peterson JL, Malebranche DJ, Lane T, Flores SA, et al. Common roots: a contextual review of HIV epidemics in black men who have sex with men across the African diaspora. Lancet. 2012;380(9839):411–23. [PubMed: 22819654]
70.
Platt L, Grenfell P, Meiksin R, Elmes J, Sherman SG, Sanders T, et al. Associations between sex work laws and sex workers’ health: a systematic review and meta-analysis of quantitative and qualitative studies. PLoS medicine. 2018;15(12):e1002680. [PMC free article: PMC6289426] [PubMed: 30532209]
71.
Santos GM, Makofane K, Arreola S, Do T, Ayala G. Reductions in access to HIV prevention and care services are associated with arrest and convictions in a global survey of men who have sex with men. Sex Transm Infect. 2017;93(1):62–4. [PubMed: 26944344]
72.
Shannon K, Strathdee SA, Goldenberg SM, Duff P, Mwangi P, Rusakova M, et al. Global epidemiology of HIV among female sex workers: influence of structural determinants. Lancet. 2015;385(9962):55–71. [PMC free article: PMC4297548] [PubMed: 25059947]
73.
Rich JD, Hogan JW, Wolf F, DeLong A, Zaller ND, Mehrotra M, et al. Lower syringe sharing and re-use after syringe legalization in Rhode Island. Drug Alcohol Depend. 2007;89(2–3):292–7. [PubMed: 17386980]
74.
Millett GA, Peterson JL, Flores SA, Hart TA, Jeffries WLt, Wilson PA, et al. Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. Lancet. 2012;380(9839):341–8. [PubMed: 22819656]
75.
Platt L, Grenfell P, Meiksin R, Elmes J, Sherman SG, Sanders T, et al. Associations between sex work laws and sex workers’ health: a systematic review and meta-analysis of quantitative and qualitative studies. PLoS Med. 2018;15(12):e1002680. [PMC free article: PMC6289426] [PubMed: 30532209]
76.
Argento E, Goldenberg S, Braschel M, Machat S, Strathdee SA, Shannon K. The impact of end-demand legislation on sex workers’ access to health and sex worker-led services: a community-based prospective cohort study in Canada. PloS One. 2020;15(4):e0225783. [PMC free article: PMC7135091] [PubMed: 32251452]
77.
Piot P, Karim SSA, Hecht R, Legido-Quigley H, Buse K, Stover J, et al. Defeating AIDS—advancing global health. Lancet. 2015;386(9989):171–218. [PubMed: 26117719]
78.
Stannah J, Dale E, Elmes J, Staunton R, Beyrer C, Mitchell KM, et al. HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysis. Lancet HIV. 2019;6(11):e769–e87. [PMC free article: PMC6993044] [PubMed: 31601542]
79.
Prevention and treatment of HIV and other sexually transmitted infections among men who have sex with men and transgender people. Geneva: World Health Organization; 2011. [PubMed: 26158187]
80.
King WM, Gamarel KE. A scoping review examining social and legal gender affirmation and health among transgender populations. Transgend Health. 2021;6(1):5–22. [PMC free article: PMC7906235] [PubMed: 33644318]
81.
Key programmes to reduce stigma and discrimination and increase access to justice in national HIV responses: Guidance Note. Geneva: Joint United Nations Programme on HIV/AIDS; 2012.
82.
Joint statement on compulsory drug detention and rehabilitation centres. Geneva: Joint United Nations Programme on HIV/AIDS; 2012.
83.
Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users – 2012 revision. Geneva: World Health Organization; 2012.
84.
Prevention and treatment of HIV and other sexually transmitted infections for sex workers in low and middle-income countries: recommendations for a public health approach. Geneva: World Health Organization; 2012. [PubMed: 26131541]
85.
Effectiveness of interventions to address HIV in prisons. Geneva: World Health Organization; 2007.
86.
Nyblade L, Stockton MA, Giger K, Bond V, Ekstrand ML, Lean RM, et al. Stigma in health facilities: why it matters and how we can change it. BMC Medicine. 2019;17(1):25. [PMC free article: PMC6376713] [PubMed: 30764806]
87.
Yam EA, Pulerwitz J, Almonte D, García F, del Valle A, Colom A, et al. Stigma among key populations living with HIV in the Dominican Republic: experiences of people of Haitian descent, MSM, and female sex workers. AIDS. 2020;34:S43–S51. [PubMed: 32881793]
88.
Rogers S, Tureski K, Cushnie A, Brown A, Bailey A, Palmer Q. Layered stigma among health-care and social service providers toward key affected populations in Jamaica and The Bahamas. AIDS Care. 2014;26(5):538–46. [PubMed: 24125067]
89.
Peitzmeier SM, Grosso A, Bowes A, Ceesay N, Baral SD. Associations of stigma with negative health outcomes for people living with HIV in the Gambia: implications for key populations. J Acquir Immune Defic Syndr. 2015;68:S146–S53. [PubMed: 25723979]
90.
Lyons CE, Olawore O, Turpin G, Coly K, Ketende S, Liestman B, et al. Intersectional stigmas and HIV-related outcomes among a cohort of key populations enrolled in stigma mitigation interventions in Senegal. AIDS. 2020;34(1):S63. [PMC free article: PMC7880051] [PubMed: 32881795]
91.
Krishnaratne S, Bond V, Stangl A, Pliakas T, Mathema H, Lilleston P, et al. Stigma and judgment toward people living with HIV and key population groups among three cadres of health workers in South Africa and Zambia: analysis of data from the HPTN 071 (PopART) trial. AIDS Patient Care STDs. 2020;34(1):38–50. [PMC free article: PMC6983735] [PubMed: 31944852]
92.
Friedland BA, Sprague L, Nyblade L, Baral SD, Pulerwitz J, Gottert A, et al. Measuring intersecting stigma among key populations living with HIV: implementing the people living with HIV Stigma Index 2.0. J Int AIDS Soc. 2018;21(5). [PMC free article: PMC6055043] [PubMed: 30033563]
93.
Fitzgerald-Husek A, Van Wert MJ, Ewing WF, Grosso AL, Holland CE, Katterl R, et al. Measuring stigma affecting sex workers (SW) and men who have sex with men (MSM): a systematic review. PloS One. 2017;12(11):e0188393. [PMC free article: PMC5708696] [PubMed: 29190642]
94.
Costa AB, de Moura Filho JB, Silva JM, Beloqui JA, Espindola Y, de Araujo CF, et al. Key and general population HIV-related stigma and discrimination in HIV-specific health care settings: results from the Stigma Index Brazil. AIDS Care. 2021:1–5. [PubMed: 33487011]
95.
Lan CW, Lin C, Thanh DC, Li L. Drug-related stigma and access to care among people who inject drugs in Vietnam. Drug Alcohol Rev. 2018;37(3):333–9. [PMC free article: PMC5794669] [PubMed: 28762584]
96.
Stringer KL, Baker EH. Stigma as a barrier to substance abuse treatment among those with unmet need: an analysis of parenthood and marital status. J Fam Issues. 2018;39(1):3–27. [PMC free article: PMC5754000] [PubMed: 29307947]
97.
Rueda S, Mitra S, Chen S, Gogolishvili D, Globerman J, Chambers L, et al. Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses. BMJ open. 2016;6(7):e011453. [PMC free article: PMC4947735] [PubMed: 27412106]
98.
Hatzenbuehler ML, O’cleirigh C, Mayer KH, Mimiaga MJ, Safren SA. Prospective associations between HIV-related stigma, transmission risk behaviors, and adverse mental health outcomes in men who have sex with men. Ann Behav Med. 2011;42(2):227–34. [PMC free article: PMC3651589] [PubMed: 21533623]
99.
Lekas H-M, Siegel K, Leider J. Felt and enacted stigma among HIV/HCV-coinfected adults: the impact of stigma layering. Qual Health Res. 2011;21(9):1205–19. [PMC free article: PMC4323279] [PubMed: 21498828]
100.
Ayhan CHB, Bilgin H, Uluman OT, Sukut O, Yilmaz S, Buzlu S. A systematic review of the discrimination against sexual and gender minority in health care settings. Int J Health Serv. 2020;50(1):44–61. [PubMed: 31684808]
101.
Magno L, Silva LAVd, Veras MA, Pereira-Santos M, Dourado I. Stigma and discrimination related to gender identity and vulnerability to HIV/AIDS among transgender women: a systematic review. Cadernos de Saude Publica. 2019;35. [PubMed: 30994744]
102.
Hughto JMW, Reisner SL, Pachankis JE. Transgender stigma and health: a critical review of stigma determinants, mechanisms, and interventions. Soc Sci Med. 2015;147:222–31. [PMC free article: PMC4689648] [PubMed: 26599625]
103.
Srithanaviboonchai K, Stockton M, Pudpong N, Chariyalertsak S, Prakongsai P, Chariyalertsak C, et al. Building the evidence base for stigma and discrimination-reduction programming in Thailand: development of tools to measure healthcare stigma and discrimination. BMC Public Health. 2017;17(1):1–11. [PMC free article: PMC5346237] [PubMed: 28284184]
104.
Siegel J, Yassi A, Rau A, Buxton JA, Wouters E, Engelbrecht MC, et al. Workplace interventions to reduce HIV and TB stigma among health care workers – where do we go from here? Glob Public Health. 2015;10(8):995–1007. [PubMed: 25769042]
105.
Pulerwitz J, Oanh KTH, Akinwolemiwa D, Ashburn K, Nyblade L. Improving hospital-based quality of care by reducing HIV-related stigma: evaluation results from Vietnam. AIDS Behav. 2015;19(2):246–56. [PubMed: 25382350]
106.
Odeny TA, Penner J, Lewis-Kulzer J, Leslie HH, Shade SB, Adero W, et al. Integration of HIV care with primary health care services: effect on patient satisfaction and stigma in rural Kenya. AIDS Res Treat. 2013;(7):485715. [PMC free article: PMC3664481] [PubMed: 23738055]
107.
Mak WW, Cheng SS, Law RW, Cheng WW, Chan F. Reducing HIV-related stigma among health-care professionals: a game-based experiential approach. AIDS Care. 2015;27(7):855–9. [PubMed: 25671591]
108.
Li L, Lin C, Guan J, Wu Z. Implementing a stigma reduction intervention in healthcare settings. J Int AIDS Soc. 2013;16:18710. [PMC free article: PMC3833117] [PubMed: 24242261]
109.
Li L, Liang L-J, Wu Z, Lin C, Guan J. Assessing outcomes of a stigma-reduction intervention with venue-based analysis. Soc psychiatry psychiatr Epidemiol. 2014;49(6):991–9. [PMC free article: PMC4031272] [PubMed: 24374721]
110.
Happell B, Byrne L, Platania-Phung C, Harris S, Bradshaw J, Davies J. Lived-experience participation in nurse education: reducing stigma and enhancing popularity. Int J Ment Health Nurs. 2014;23(5):427–34. [PubMed: 24898260]
111.
Geibel S, Hossain SM, Pulerwitz J, Sultana N, Hossain T, Roy S, et al. Stigma reduction training improves healthcare provider attitudes toward, and experiences of, young marginalized people in Bangladesh. J Adolesc Health. 2017;60(2):S35–S44. [PubMed: 28109339]
112.
Flanagan EH, Buck T, Gamble A, Hunter C, Sewell I, Davidson L. “Recovery speaks”: a photovoice intervention to reduce stigma among primary care providers. Psychiatr Serv. 2016;67(5):566–9. [PubMed: 26766754]
113.
Fernandez A, Tan K-A, Knaak S, Chew BH, Ghazali SS. Effects of brief psychoeducational program on stigma in Malaysian pre-clinical medical students: a randomized controlled trial. Acad Psychiatry. 2016;40(6):905–11. [PubMed: 27527730]
114.
Batey DS, Whitfield S, Mulla M, Stringer KL, Durojaiye M, McCormick L, et al. Adaptation and implementation of an intervention to reduce HIV-related stigma among healthcare workers in the United States: piloting of the FRESH workshop. AIDS Patient Care and STDs. 2016;30(11):519–27. [PMC free article: PMC5116658] [PubMed: 27849373]
115.
Stangl AL, Lloyd JK, Brady LM, Holland CE, Baral S. A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: How far have we come? J Int AIDS Soc. 2013;16:18734. [PMC free article: PMC3833106] [PubMed: 24242268]
116.
Nyblade L, Stangl A, Weiss E, Ashburn K. Combating HIV stigma in health care settings: what works? J Int AIDS Soc. 2009;12(1):1–7. [PMC free article: PMC2731724] [PubMed: 19660113]
117.
Feyissa GT, Lockwood C, Woldie M, Munn Z. Reducing HIV-related stigma and discrimination in healthcare settings: a systematic review of guidelines, tools, standards of practice, best practices, consensus statements and systematic reviews. J Multidiscip Healthc. 2018;11:405–16. [PMC free article: PMC6118284] [PubMed: 30214222]
118.
HIV and adolescents: guidance for HIV testing and counselling and care for adolescents living with HIV: recommendations for a public health approach and considerations for policy makers and managers. Geneva: World Health Organization; 2013. [PubMed: 25032477]
119.
UNAIDS guidance note on HIV and sex work. Geneva: Joint United Nations Programme on HIV/AIDS; 2012.
120.
HIV and adolescents: guidance for HIV testing and counselling and care for adolescents living with HIV: recommendations for a public health approach and considerations for policy makers and managers. Geneva: World Health Organization; 2013. [PubMed: 25032477]
121.
Giving young people the information, skills and knowledge they need. Comprehensive sexuality education. New York: United Nations Population Fund; 2013.
122.
Wirtz AL, Pretorius C, Beyrer C, Baral S, Decker MR, Sherman SG, et al. Epidemic impacts of a community empowerment intervention for HIV prevention among female sex workers in generalized and concentrated epidemics. PLoS One. 2014;9(2):e88047. [PMC free article: PMC3916392] [PubMed: 24516580]
123.
Shannon K, Crago A-L, Baral SD, Bekker L-G, Kerrigan D, Decker MR, et al. The global response and unmet actions for HIV and sex workers. Lancet. 2018;392(10148):698–710. [PMC free article: PMC6384122] [PubMed: 30037733]
124.
Platteau T, van Lankveld J, Apers L, Fransen K, Rockstroh J, Florence E. HIV testing for key populations in Europe: a decade of technological innovation and patient empowerment complement the role of health care professionals. HIV Medicine. 2018;19:71–6. [PubMed: 29488698]
125.
Mehrotra A, Davis DA, Evens E, White B, Wilcher R. The importance of key population community engagement and empowerment in HIV programming: insights from a global survey with local implementing partners. J Glob Health Reports. 2020;4:e2020044.
126.
Laverack G. Improving health outcomes through community empowerment: a review of the literature. J Health, Popul Nutr. 2006:113–20. [PubMed: 16796158]
127.
Kerrigan D, Fonner VA, Stromdahl S, Kennedy CE. Community empowerment among female sex workers is an effective HIV prevention intervention: a systematic review of the peer-reviewed evidence from low-and middle-income countries. AIDS Behav. 2013;17(6):1926–40. [PubMed: 23539185]
128.
Kerrigan D, Mbwambo J, Likindikoki S, Davis W, Mantsios A, Beckham SW, et al. Project Shikamana: community empowerment-based combination HIV prevention significantly impacts HIV incidence and care continuum outcomes among female sex workers in Iringa, Tanzania. J Acquir Immune Defic Syndr 2019;82(2):141. [PMC free article: PMC7393302] [PubMed: 31513552]
129.
Kerrigan D, Kennedy CE, Morgan-Thomas R, Reza-Paul S, Mwangi P, Win KT, et al. A community empowerment approach to the HIV response among sex workers: effectiveness, challenges, and considerations for implementation and scale-up. Lancet. 2015;385(9963):172–85. [PMC free article: PMC7394498] [PubMed: 25059938]
130.
Kerrigan D, Donastorg Y, Barrington C, Perez M, Gomez H, Mbwambo J, et al. Assessing and addressing social determinants of HIV among female sex workers in the Dominican Republic and Tanzania through community empowerment-based responses. Current HIV/AIDS Reports. 2020;17(2):88–96. [PMC free article: PMC7144872] [PubMed: 32072467]
131.
Hays RB, Rebchook GM, Kegeles SM. The Mpowerment Project: Community-building with young gay and bisexual men to prevent HIV. Am J Community Psychol. 2003;31(3):301–12. [PubMed: 12866687]
132.
Beckham SW, Stockton M, Galai N, Davis W, Mwambo J, Likindikoki S, et al. Family planning use and correlates among female sex workers in a community empowerment HIV prevention intervention in Iringa, Tanzania: a case for tailored programming. BMC Public Health. 2021;21(1):1–11. [PMC free article: PMC8274018] [PubMed: 34247614]
133.
Baral S, Holland CE, Shannon K, Logie C, Semugoma P, Sithole B, et al. Enhancing benefits or increasing harms: community responses for HIV among men who have sex with men, transgender women, female sex workers, and people who inject drugs. J Acquir Immune Defic Syndr. 2014;66:S319–S28. [PubMed: 25007203]
134.
Chang J, Shelly S, Busz M, Stoicescu C, Iryawan AR, Madybaeva D, et al. Peer driven or driven peers? A rapid review of peer involvement of people who use drugs in HIV and harm reduction services in low- and middle-income countries. Harm Reduct J. 2021;18(1):15. [PMC free article: PMC7857348] [PubMed: 33536033]
135.
World Health Organization, United Nations Population Fund, Joint United Nations Programme on HIV/AIDS, Global Network of Sex Work Projects, The World Bank. Implementing comprehensive HIV/STI programmes with sex workers: practical approaches from collaborative interventions. Geneva: World Health Organization; 2013.
136.
United Nations Population Fund, Global Forum on MSM & HIV, United Nations Development Programme, World Health Organization, United States Agency for International Development, World Bank. Implementing comprehensive HIV and STI programmes with men who have sex with men: practical guidance for collaborative interventions. New York: United Nations Population Fund; 2015.
137.
United Nations Office on Drugs and Crime, International Network of People Who Use Drugs, Joint United Nations Programme on HIV/AIDS, United Nations Development Programme, United Nations Population Fund, World Health Organization, et al. Implementing comprehensive HIV and HCV programmes with people who inject drugs: practical guidance for collaborative interventions. Vienna: United Nations Office on Drugs and Crime; 2017.
138.
United Nations Development Programme, IRGT: A Global Network of Transgender Women and HIV, United Nations Population Fund, UCSF Center of Excellence for Transgender Health, Johns Hopkins Bloomberg School of Public Health, World Health Organization, et al. Implementing comprehensive HIV and STI programmes with transgender people: practical guidance for collaborative interventions. New York: United Nations Development Programme; 2016.
139.
Establishing community-led monitoring of HIV services. Geneva: Joint United Nations Programme on HIV/AIDS; 2021.
140.
Blondeel K, De Vasconcelos S, García-Moreno C, Stephenson R, Temmerman M, Toskin I. Violence motivated by perception of sexual orientation and gender identity: a systematic review. Bull World Health Org. 2018;96(1):29. [PMC free article: PMC5791869] [PubMed: 29403098]
141.
Sherwood JA, Grosso A, Decker MR, Peitzmeier S, Papworth E, Diouf D, et al. Sexual violence against female sex workers in The Gambia: a cross-sectional examination of the associations between victimization and reproductive, sexual and mental health. BMC Public Health. 2015;15(1):1–10. [PMC free article: PMC4375842] [PubMed: 25886187]
142.
Nelson E-UE, Brown AS. Extra-legal policing strategies and HIV risk environment: accounts of people who inject drugs in Nigeria. Drugs: Educ Prev Policy. 2020;27(4):312–9.
143.
Miltz AR, Lampe FC, Bacchus LJ, McCormack S, Dunn D, White E, et al. Intimate partner violence, depression, and sexual behaviour among gay, bisexual and other men who have sex with men in the PROUD trial. BMC Public Health. 2019;19(1):1–17. [PMC free article: PMC6482482] [PubMed: 31023281]
144.
Griner SB, Vamos CA, Thompson EL, Logan R, Vázquez-Otero C, Daley EM. The intersection of gender identity and violence: victimization experienced by transgender college students. J Interpers Violence. 2020;35(23–24):5704–25. [PubMed: 29294863]
145.
Finneran C, Stephenson R. Intimate partner violence among men who have sex with men: a systematic review. Trauma Violence Abuse. 2013;14(2):168–85. [PMC free article: PMC4046894] [PubMed: 23271429]
146.
Dasgupta S. Violence in commercial sex work: a case study on the impact of violence among commercial female sex workers in india and strategies to combat violence. Violence Against Women. 2020:1077801220969881. [PubMed: 33263505]
147.
Poteat T, Ackerman B, Diouf D, Ceesay N, Mothopeng T, Odette K-Z, et al. HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: A cross-sectional analysis. PLoS medicine. 2017;14(11):e1002422. [PMC free article: PMC5675306] [PubMed: 29112689]
148.
Smith LR, Yore J, Triplett DP, Urada L, Nemoto T, Raj A. Impact of sexual violence across the lifespan on HIV risk behaviors among transgender women and cisgender people living with HIV. J Acquir Immune Defic Syndr (1999). 2017;75(4):408. [PMC free article: PMC5810354] [PubMed: 28653970]
149.
Peitzmeier SM, Malik M, Kattari SK, Marrow E, Stephenson R, Agénor M, et al. Intimate partner violence in transgender populations: systematic review and meta-analysis of prevalence and correlates. Am J Public Health. 2020;110(9):e1–e14. [PMC free article: PMC7427218] [PubMed: 32673114]
150.
Park JN, Linton SL, Sherman SG, German D. Police violence among people who inject drugs in Baltimore, Maryland. Int J Drug Policy. 2019;64:54–61. [PMC free article: PMC8370125] [PubMed: 30579221]
151.
Lunze K, Lunze FI, Raj A, Samet JH. Stigma and human rights abuses against people who inject drugs in Russia – a qualitative investigation to inform policy and public health strategies. PloS One. 2015;10(8):e0136030. [PMC free article: PMC4549320] [PubMed: 26305697]
152.
Lee JO, Yoon Y, Idrisov B, Kiriazova T, Makarenko O, Sereda Y, et al. Violence, HIV risks, and polysubstance use among HIV-positive people who inject drugs in Ukraine. AIDS Behav. 2021;25(7):2120–30. [PMC free article: PMC9184239] [PubMed: 33385280]
153.
Dunkle KL, Wong FY, Nehl EJ, Lin L, He N, Huang J, et al. Male-on-male intimate partner violence and sexual risk behaviors among money boys and other men who have sex with men in Shanghai, China. Sex Transm Dis. 2013;40(5):362–5. [PMC free article: PMC8080435] [PubMed: 23588124]
154.
Davis DA, Morales GJ, Ridgeway K, Mendizabal M, Lanham M, Dayton R, et al. The health impacts of violence perpetrated by police, military and other public security forces on gay, bisexual and other men who have sex with men in El Salvador. Cult Health Sex. 2020;22(2):217–32. [PubMed: 30957697]
155.
Sazzad HM, McCredie L, Treloar C, Lloyd AR, Lafferty L. Violence and hepatitis C transmission in prison – a modified social ecological model. PloS One. 2020;15(12):e0243106. [PMC free article: PMC7707477] [PubMed: 33259565]
156.
Russell M, Chen M-J, Nochajski TH, Testa M, Zimmerman SJ, Hughes PS. Risky sexual behavior, bleeding caused by intimate partner violence, and hepatitis C virus infection in patients of a sexually transmitted disease clinic. Am J Public Health. 2009;99(S1):S173–S9. [PMC free article: PMC2724935] [PubMed: 19218181]
157.
Decker MR, Wirtz AL, Baral SD, Peryshkina A, Mogilnyi V, Weber RA, et al. Injection drug use, sexual risk, violence and STI/HIV among Moscow female sex workers. Sex Transm Infect. 2012;88(4):278–83. [PMC free article: PMC3628729] [PubMed: 22287530]
158.
Decker MR, Wirtz AL, Pretorius C, Sherman SG, Sweat MD, Baral SD, et al. Estimating the impact of reducing violence against female sex workers on HIV epidemics in Kenya and Ukraine: a policy modeling exercise. Am J Reprod Immunol. 2013;69:122–32. [PubMed: 23387931]
159.
El-Bassel N, Wechsberg WM, Shaw SA. Dual HIV risk and vulnerabilities among women who use or inject drugs: no single prevention strategy is the answer. Curr Opin HIV AIDS. 2012;7(4):326. [PMC free article: PMC6330012] [PubMed: 22498480]
160.
Evidence Brief: Violence against women. Intimate partner and sexual violence against women. Geneva: World Health Organization; 2019.
161.
Caring for women subjected to violence: a WHO curriculum for training health-care providers. Geneva: World Health Organization; 2019.
162.
Responding to intimate partner violence and sexual violence against women: WHO clinical and policy guidelines. Geneva: World Health Organization; 2013. [PubMed: 24354041]
163.
Ando N, Mizushima D, Watanabe K, Takano M, Shiojiri D, Uemura H, et al. Modified self-obtained pooled sampling to screen for Chlamydia trachomatis and Neisseria gonorrhoeae infections in men who have sex with men. Sex Transm Infect. 2020;20:20. [PubMed: 33082236]
164.
Handbook on police accountability, oversight and integrity. Vienna: United Nations Office on Drugs and Crime; 2011.
165.
Ellsberg M, Arango DJ, Morton M, Gennari F, Kiplesund S, Contreras M, et al. Prevention of violence against women and girls: what does the evidence say? Lancet. 2015;385(9977):1555–66. [PubMed: 25467575]
166.
Implementation of the joint commitment to effectively addressing and countering the world drug problem with regards to human rights (A/HRC/39/39). UN Human Rights Council; 2018.
167.
Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Geneva: World Health Organization; 2004.
168.
Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva: World Health Organization; 2012. [PubMed: 23805439]
169.
Guidelines for the psyschosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009. [PubMed: 23762965]
170.
Interventions to address HIV in prions: prevention of sexual transmission. Geneva: World Health Organization; 2007.
171.
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. Geneva: World Health Organization; 2021. [PubMed: 34370423]
172.
Guidelines for long-acting injectable cabotegravir for HIV prevention. Geneva: World Health Organization; 2022. [PubMed: 36417549]
173.
Responding to intimate partner violence and sexual violence against women: WHO clinical and policy guidelines. Geneva: World Health Organization; 2013. [PubMed: 24354041]
174.
WHO guidelines for the treatment of Treponema pallidum (syphilis) Geneva: World Health Organization; 2016. [PubMed: 27631046]
175.
Consolidated guidelines on HIV testing services. Geneva: World Health Organization; 2019. [PubMed: 27977094]
176.
Dual HIV/syphilis rapid diagnostic tests can be used as the first test in antenatal care. Geneva: World Health Organization; 2019.
177.
Guidelines for the Treatment of Treponema pallidum (syphilis). Geneva: World Health Organization; 2016. [PubMed: 27631046]
178.
Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020. [PubMed: 32833415]
179.
Coomes, David Michael, Dylan Green, Ruanne Barnabas, Monisha Sharma, Magdalena Barr-Dichiara, Muhammad S. Jamil, Rachel Baggaley et al. “Cost-effectiveness of implementing HIV and HIV/syphilis dual testing among key populations in Viet Nam: a modeling analysis.” medRxiv (2022). [PMC free article: PMC9379490] [PubMed: 35953255]
180.
Youth-centred digital health interventions: a framework for planning, developing and implementing solutions with and for young people. Geneva: World Health Organization; 2021.
181.
WHO information note on the use of dual HIV/syphilis rapid diagnostic tests (RDT). Geneva: World Health Organization; 2017.
182.
WHO guideline on self-care interventions for health and well-being. Geneva: World Health Organization; 2021. [PubMed: 34370426]
183.
Guidelines for the management of symptomatic sexually transmitted infections. Geneva: World Health Organization; 2021. [PubMed: 34370424]
184.
Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017.
185.
Recommendations and guidance on hepatitis C virus self-testing. Geneva: World Health Organization; 2021. [PubMed: 34370425]
186.
Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Van Lunzen J, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81. [PubMed: 27404185]
187.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. [PMC free article: PMC3200068] [PubMed: 21767103]
188.
Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–e47. [PubMed: 30025681]
189.
WHO consolidated guidelines on tuberculosis: Module 2: Screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2020. [PubMed: 33822560]
190.
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021. Report No. 9240031596. [PubMed: 34370423]
191.
WHO Consolidated guidelines on tuberculosis: Module 4: Treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. [PubMed: 32603040]
192.
WHO consolidated guidelines on tuberculosis: Module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization; 2020. [PubMed: 32186832]
193.
Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018. [PubMed: 30307724]
194.
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015. [PubMed: 26225396]
195.
Grulich AE, Van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67. [PubMed: 17617273]
196.
World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19).
197.
Medical eligibility criteria for contraceptive use. Geneva: World Health Organization; 2015. [PubMed: 26447268]
198.
WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Geneva: World Health Organization; 2021. [PubMed: 34314129]
199.
New WHO recommendations on screening and treatment to prevent cervical cancer among women living with HIV. Geneva: World Health Organization; 2021.
200.
Abortion care guideline. Geneva: World Health Organization; 2022. [PubMed: 35344310]
201.
mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings: mental health gap action programme (mhGAP). World Health Organization; 2016. [PubMed: 27786430]
202.
203.
United Nations General Assembly. Convention on the Rights of the Child. Geneva: 1989.
204.
HIV and young people who sell sex: a technical brief. Geneva: World Health Organization; 2015.
205.
Rashti R, Alavian SM, Moradi Y, Sharafi H, Bolbanabad AM, Roshani D, et al. Global prevalence of HCV and/or HBV coinfections among people who inject drugs and female sex workers who live with HIV/AIDS: a systematic review and meta-analysis. Arch Virol. 2020:1–12. [PubMed: 32617764]
206.
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–e207. [PMC free article: PMC5683738] [PubMed: 29074409]
207.
Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58(4):1215–24. [PMC free article: PMC3723697] [PubMed: 23504650]
208.
Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208–e20. [PMC free article: PMC5683737] [PubMed: 29074410]
209.
Värmå Falk M, Strömdahl S, Ekström AM, Kåberg M, Karlsson N, Dahlborn H, et al. A qualitative study of facilitators and barriers to participate in a needle exchange program for women who inject drugs. Harm Reduct J. 2020;17(1):84. [PMC free article: PMC7579804] [PubMed: 33092595]
210.
DeBeck K, Cheng T, Montaner JS, Beyrer C, Elliott R, Sherman S, et al. HIV and the criminalisation of drug use among people who inject drugs: a systematic review. Lancet HIV. 2017;4(8):e357–e74. [PMC free article: PMC6005363] [PubMed: 28515014]
211.
Grenfell P, Baptista Leite R, Garfein R, de Lussigny S, Platt L, Rhodes T. Tuberculosis, injecting drug use and integrated HIV-TB care: a review of the literature. Drug Alcohol Depend. 2013;129(3):180–209. [PubMed: 23306095]
212.
Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M. Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV AIDS. 2012;7(4):345–53. [PubMed: 22678489]
213.
Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis. 2018;18(1):79. [PMC free article: PMC5809955] [PubMed: 29433454]
214.
Ooi C, Kong FYS, Lewis DA, Hocking JS. Prevalence of sexually transmissible infections and HIV in men attending sex-on-premises venues in Australia: a systematic review and meta-analysis of observational studies. Sex Health. 2020;17(2):135–48. [PubMed: 32228828]
215.
Beebeejaun K, Degala S, Balogun K, Simms I, Woodhall SC, Heinsbroek E, et al. Outbreak of hepatitis A associated with men who have sex with men (MSM), England, July 2016 to January 2017. Eurosurveillance. 2017;22(5):30454. [PMC free article: PMC5388117] [PubMed: 28183392]
216.
Chen G-J, Lin K-Y, Hung C-C, Chang S-C. Hepatitis A outbreak among men who have sex with men in a country of low endemicity of hepatitis A infection. J Infect Dis. 2017;215(8):1339–40. [PubMed: 28329351]
217.
Freidl GS, Sonder GJ, Bovée LP, Friesema IH, van Rijckevorsel GG, Ruijs WL, et al. Hepatitis A outbreak among men who have sex with men (MSM) predominantly linked with the EuroPride, the Netherlands, July 2016 to February 2017. Eurosurveillance. 2017;22(8):30468. [PMC free article: PMC5356436] [PubMed: 28251892]
218.
Ndumbi P, Freidl GS, Williams CJ, Mårdh O, Varela C, Avellón A, et al. Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European Union and European Economic Area, June 2016 to May 2017. Eurosurveillance. 2018;23(33):1700641. [PMC free article: PMC6205254] [PubMed: 30131095]
219.
Werber D, Michaelis K, Hausner M, Sissolak D, Wenzel J, Bitzegeio J, et al. Ongoing outbreaks of hepatitis A among men who have sex with men (MSM), Berlin, November 2016 to January 2017 – linked to other German cities and European countries. Eurosurveillance. 2017;22(5):30457. [PMC free article: PMC5388120] [PubMed: 28183391]
220.
Asher AK, Portillo CJ, Cooper BA, Dawson-Rose C, Vlahov D, Page KA. Clinicians’ views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Subst Use Misuse. 2016;51(9):1218–23. [PMC free article: PMC6907073] [PubMed: 27219274]
221.
Malekinejad M, Barker EK, Merai R, Lyles CM, Bernstein KT, Sipe TA, et al. Risk of HIV acquisition among men who have sex with men infected with bacterial sexually transmitted infections: a systematic review and meta-analysis. Sex Transm Dis. 2021;48(10):e138–e48. [PMC free article: PMC8485981] [PubMed: 33783414]
222.
Reisner SL, Radix A, Deutsch MB. Integrated and gender-affirming transgender clinical care and research. J Acquir Immune Defic Syndr (1999). 2016;72(3):S235–S42. [PMC free article: PMC4969060] [PubMed: 27429189]
223.
Wirtz AL, Poteat TC, Malik M, Glass N. Gender-based violence against transgender people in the United States: a call for research and programming. Trauma Violence Abuse. 2020;21(2):227–41. [PubMed: 29439615]
224.
Mendes WG, Silva C. Homicide of lesbians, gays, bisexuals, travestis, transexuals, and transgender people (LGBT) in Brazil: a spatial analysis. Cien Saude Colet. 2020;25(5):1709–22. [PubMed: 32402041]
225.
Dinno A. Homicide rates of transgender individuals in the United States: 2010–2014. Am J Public Health. 2017;107(9):1441–7. [PMC free article: PMC5551594] [PubMed: 28727530]
226.
Rodríguez-Madera SL, Padilla M, Varas-Díaz N, Neilands T, Vasques Guzzi AC, Florenciani EJ, et al. Experiences of violence among transgender women in Puerto Rico: an underestimated problem. J Homosex. 2017;64(2):209–17. [PMC free article: PMC5546874] [PubMed: 27054395]
227.
Nobili A, Glazebrook C, Arcelus J. Quality of life of treatment-seeking transgender adults: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2018;19(3):199–220. [PMC free article: PMC6223813] [PubMed: 30121881]
228.
Kelley J. Stigma and human rights: transgender discrimination and its influence on patient health. Prof Case Manag. 2021;26(6):298–303. [PubMed: 34609343]
229.
Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22. [PubMed: 23260128]
230.
Ghobad M, Marzieh S, Roya R, Hojat D, Elham N, Farima Z, et al. Euro J Med Res. 2021.
231.
Van Schuylenbergh J, Motmans J, Defreyne J, Somers A, T’Sjoen G. Sexual health, transition-related risk behavior and need for health care among transgender sex workers. Int J Transgend. 2019;20(4):388–402. [PMC free article: PMC6913627] [PubMed: 32999624]
232.
Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012;9(10):2641–51. [PubMed: 22906135]
233.
Wallace PM, Rasmussen S. Analysis of adulterated silicone: implications for health promotion. Int J Transgend. 2010;12(3):167–75.
234.
Aguayo-Romero RA, Reisen CA, Zea MC, Bianchi FT, Poppen PJ. Gender affirmation and body modification among transgender persons in Bogotá, Colombia. Int J Transgend. 2015;16(2):103–15. [PMC free article: PMC4733647] [PubMed: 26839525]
235.
Ngoc M-AT, Greenberg K, Alio PA, McIntosh S, Baldwin C. Non-medical body modification (body-mod) strategies among transgender and gender diverse (TG/GD) adolescents and young adults. J Adolescent Health. 2020;66(2):S84.
236.
International statistical classification of diseases and related health problems (ICD–11). Geneva: World Health Organization; 2019.
237.
Prisons and health. Vienna: United Nations Office on Drugs and Crime; 2014.
238.
Ahmadi Gharaei H, Fararouei, M., Mirzazadeh, A. et al. The global and regional prevalence of hepatitis C and B co-infections among prisoners living with HIV: a systematic review and meta-analysis. Infect Dis Poverty 2021;10:93. [PMC free article: PMC8252262] [PubMed: 34210349]
239.
Sander G, Shirley-Beavan S, Stone K. The global state of harm reduction in prisons. J Correct Health Care. 2019;25(2):105–20. [PubMed: 31084277]
240.
Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006;101(2):181–91. [PubMed: 16445547]
241.
Dolan K, Khoei EM, Brentari C, Stevens A. Prisons and drugs: a global review of incarceration, drug use and drug services. Report 12. 2007.
242.
Fazel S, Hayes AJ, Bartellas K, Clerici M, Trestman R. Mental health of prisoners: prevalence, adverse outcomes, and interventions. Lancet Psychiatry. 2016;3(9):871–81. [PMC free article: PMC5008459] [PubMed: 27426440]
243.
The United Nations standard minimum rules for the treatment of prisoners (the Nelson Mandela Rules). United Nations Office on Drugs and Crime, Vienna; 2016.
244.
Prisons and Health. Denmark: World Health Organization (Europe); 2014.
245.
HIV prevention, testing, treatment, care and support in prisons and other closed settings: a comprehensive package of interventions. Vienna: United Nations Office on Drugs and Crime; 2020.
246.
HIV/AIDS JUNPo. Progress report of the multistakeholder task team on community-led AIDS responses. Geneva: UNAIDS; 2020.
247.
Nguyen VTT, Phan HT, Kato M, Nguyen QT, Le Ai KA, Vo SH, et al. Community-led HIV testing services including HIV self-testing and assisted partner notification services in Vietnam: lessons from a pilot study in a concentrated epidemic setting. J Int AIDS Soc. 2019;22(3):e25301. [PMC free article: PMC6639698] [PubMed: 31321903]
248.
Vannakit R, Janyam S, Linjongrat D, Chanlearn P, Sittikarn S, Pengnonyang S, et al. Give the community the tools and they will help finish the job: key population-led health services for ending AIDS in Thailand. J Int AIDS Soc. 2020;23(6):e25535. [PMC free article: PMC7282496] [PubMed: 32515869]
249.
Reza-Paul S, Lazarus L, Maiya R, Venukumar KT, Lakshmi B, Roy A, et al. Delivering community-led integrated HIV and sexual and reproductive health services for sex workers: a mixed methods evaluation of the DIFFER study in Mysore, South India. PLoS One. 2019;14(6):e0218654. [PMC free article: PMC6588234] [PubMed: 31226141]
250.
Phanuphak N, Sungsing T, Jantarapakde J, Pengnonyang S, Trachunthong D, Mingkwanrungruang P, et al. Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand. Sex Health. 2018;15(6):542–55. [PubMed: 30249317]
251.
Onovo A, Kalaiwo A, Emmanuel G, Keiser O. Community-led index case testing: a promising strategy to improve HIV diagnosis and linkage to care in partners of key populations in Nigeria. Available at SSRN 3872626 (accessed 24 June 2022).
252.
Stardust Z, Kolstee J, Joksic S, Gray J, Hannan S. A community-led, harm-reduction approach to chemsex: case study from Australia’s largest gay city. Sex Health. 2018;15(2):179–81. [PubMed: 29592830]
253.
Lillie TA, Persaud NE, DiCarlo MC, Gashobotse D, Kamali DR, Cheron M, et al. Reaching the unreached: performance of an enhanced peer outreach approach to identify new HIV cases among female sex workers and men who have sex with men in HIV programs in West and Central Africa. Plos One. 2019;14(4):e0213743. [PMC free article: PMC6447144] [PubMed: 30943205]
254.
Framework on integrated, people-centred health services. In: Sixty-ninth World Health Assembly, Geneva. Geneva: World Health Organization; 2016.
255.
Integrated care models: an overview. Copenhagen: World Health Organization (Europe); 2016.
256.
257.
Youth-centred digital health interventions: a framework for planning, developing and implementing solutions with and for young people. Geneva: World Health Organization; 2020.
258.
Hightow-Weidman L, Muessig K, Claude K, Roberts J, Zlotorzynska M, Sanchez T. Maximizing digital interventions for youth in the midst of covid-19: lessons from the adolescent trials network for HIV interventions. AIDS Behav. 2020;24(8):2239–43. [PMC free article: PMC7166094] [PubMed: 32306214]
259.
Ames HM, Glenton C, Lewin S, Tamrat T, Akama E, Leon N. Clients’ perceptions and experiences of targeted digital communication accessible via mobile devices for reproductive, maternal, newborn, child, and adolescent health: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2019(10). [PMC free article: PMC6791116] [PubMed: 31608981]
260.
Inhae C, Jiwon K. Effects of mHealth intervention on sexual and reproductive health in emerging adulthood: a systematic review and meta-analysis of randomized controlled trials. Int J Nurs Stud. 2021;119:103949. [PubMed: 34004469]
261.
HIV and young people who sell sex: a technical brief. Geneva: World Health Organization; 2015.
262.
HIV and young men who have sex with men. Geneva: World Health Organization; 2015.
263.
HIV and young transgender people: a technical brief. Geneva: World Health Organization; 2015.
264.
HIV and young people who inject drugs: a technical brief. Geneva: World Health Organization; 2015.
265.
Bekker LG, Johnson L, Wallace M, Hosek S. Building our youth for the future. Wiley Online Library; 2015. [PMC free article: PMC4344540] [PubMed: 25724512]
266.
Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28(10):1509–19. [PMC free article: PMC6195215] [PubMed: 24809629]
267.
Kteily-Hawa R, Hawa AC, Gogolishvili D, Al Akel M, Andruszkiewicz N, Vijayanathan H, et al. Understanding the epidemiological HIV risk factors and underlying risk context for youth residing in or originating from the Middle East and North Africa (MENA) region: a scoping review of the literature. PloS One. 2022;17(1):e0260935. [PMC free article: PMC8741013] [PubMed: 34995320]
268.
McLaughlin M, Amaya A, Klevens M, O’Cleirigh C, Batchelder A. A review of factors associated with age of first injection. J Psychoact Drugs. 2020;52(5):412–20. [PMC free article: PMC7704573] [PubMed: 32795151]
269.
Cornell M, Dovel K. Reaching key adolescent populations. Curr Opin HIV AIDS. 2018;13(3):274–80. [PMC free article: PMC5956528] [PubMed: 29432229]
270.
Young people and HIV. Geneva: Joint United Nations Programme on HIV/AIDS; 2021.
271.
Young key populations from Asia and the Pacific claiming their space at the 2021 High-Level Meeting on AIDS 2021. Joint United Nations Programme on HIV/AIDS (https://www​.unaids.org​/en/resources/presscentre​/featurestories​/2021/june/20210611​_young-key-populations-asia-pacific, accessed 14 March 2022).
272.
Weinstock HS, Kreisel KM, Spicknall IH, Chesson HW, Miller WC. STI Prevalence, incidence, and costs in the United States: new estimates, new approach. Sex Transm Dis. 2021;48(4):207. [PubMed: 33492092]
273.
Report on sexually transmitted infections in Canada, 2017. Public Health Agency of Canada; 2019.
274.
HIV, viral hepatitis and sexually transmissible infections in Australia – annual surveillance report 2018. Kirby Institute; 2020.
275.
Gonorrhoea – Annual epidemiological report for 2018. European Centre for Disease Prevention and Control; 2020.
276.
Chlamydia infection – Annual epidemiological report for 2018. European Centre for Disease Prevention and Control; 2020.
277.
Bao Y, Larney S, Peacock A, Colledge S, Grebely J, Hickman M, et al. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: a systematic review and meta-analysis. Int J Drug Policy. 2019;70:87–93. [PMC free article: PMC6679982] [PubMed: 31125802]
278.
Viral Hepatitis Surveillance – United States 2019; Centres for Disease Control and Prevention; May 2021.
279.
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–e207. [PMC free article: PMC5683738] [PubMed: 29074409]
280.
The Key Populations Atlas: UNAIDS (https://kpatlas​.unaids.org/, accessed 14 March 2022).
281.
Ie SI, Turyadi, Sidarta E, Sadhewa A, Purnomo GA, Soedarmono YS, et al. High prevalence of hepatitis B virus infection in young adults in Ternate, Eastern Indonesia. Am J Trop Med Hyg. 2015;93(6):1349–55. [PMC free article: PMC4674257] [PubMed: 26392157]
282.
Shannon CL, Klausner JD. The growing epidemic of sexually transmitted infections in adolescents: a neglected population. Curr Opin Pediatr. 2018;30(1):137. [PMC free article: PMC5856484] [PubMed: 29315111]
283.
Patton GC, Sawyer SM, Santelli JS, Ross DA, Afifi R, Allen NB, et al. Our future: a Lancet commission on adolescent health and wellbeing. Lancet. 2016;387(10036):2423–78. [PMC free article: PMC5832967] [PubMed: 27174304]
284.
Ramadhani HO, Crowell TA, Nowak RG, Ndembi N, Kayode BO, Kokogho A, et al. Association of age with healthcare needs and engagement among Nigerian men who have sex with men and transgender women: cross-sectional and longitudinal analyses from an observational cohort. J Int AIDS Soc. 2020;23:e25599. [PMC free article: PMC7527771] [PubMed: 33000907]
285.
Rucinski KB, Schwartz SR, Mishra S, Phaswana-Mafuya N, Diouf D, Mothopeng T, et al. High HIV prevalence and low HIV-service engagement among young women who sell sex: a pooled analysis across 9 Sub-Saharan African countries. J Acquir Immune Defic Syndr. 2020;85(2):148–55. [PubMed: 32639275]
286.
Ninsiima LR, Chiumia IK, Ndejjo R. Factors influencing access to and utilisation of youth-friendly sexual and reproductive health services in sub-Saharan Africa: a systematic review. Reprod Health. 2021;18(1):1–17. [PMC free article: PMC8237506] [PubMed: 34176511]
287.
Chong LSH, Kerklaan J, Clarke S, Kohn M, Baumgart A, Guha C, Tunnicliffe DJ, Hanson CS, Craig JC, Tong A. Experiences and Perspectives of Transgender Youths in Accessing Health Care: A Systematic Review. JAMA Pediatr. 2021 Nov 1;175(11):1159–1173. doi: 10.1001/jamapediatrics.2021.2061. PMID: 34279538. [PubMed: 34279538] [CrossRef]
288.
Assessment of barriers to accessing health services for disadvantaged adolescents in Nigeria. Brazzaville. WHO Regional Office for Africa; 2019.
289.
Assessment of barriers to accessing health services for disadvantaged adolescents in Tanzania. Geneva: World Health Organization; 2020.
290.
Young people and the law in Asia and the Pacific: a review of laws and policies affecting young people’s access to sexual and reproductive health and HIV services. New York: UNESCO; 2013.
291.
Barr-DiChiara M, Tembo M, Harrison L, Quinn C, Ameyan W, Sabin K, et al. Adolescents and age of consent to HIV testing: an updated review of national policies in sub-Saharan Africa. BMJ Open. 2021;11(9):e049673. [PMC free article: PMC8442095] [PubMed: 34489284]
292.
Robert K, Maryline M, Jordan K, Lina D, Helgar M, Annrita I, et al. Factors influencing access of HIV and sexual and reproductive health services among adolescent key populations in Kenya. Int J Public Health. 2020;65(4):425–32. [PMC free article: PMC7275021] [PubMed: 32337631]
293.
Shabani O, Moleki MM, Thupayagale-Tshweneagae GG. Individual determinants associated with utilisation of sexual and reproductive health care services for HIV and AIDS prevention by male adolescents. Curationis. 2018;41(1):1–6. [PMC free article: PMC6111545] [PubMed: 30198290]
294.
Delany-Moretlwe S, Cowan FM, Busza J, Bolton-Moore C, Kelley K, Fairlie L. Providing comprehensive health services for young key populations: needs, barriers and gaps. J Int AIDS Soc. 2015;18:19833. [PMC free article: PMC4344539] [PubMed: 25724511]
295.
Guidance on ethical considerations in planning and reviewing research studies on sexual and reproductive health in adolescents. Geneva: World Health Organization; 2018. [PMC free article: PMC6496912] [PubMed: 30904091]
296.
Handbook for conducting an adolescent health services barriers assessment (AHSBA) with a focus on disadvantaged adolescents. Geneva: World Health Organization; 2019.
297.
World Health Organization, IA Society. A global research agenda for adolescents living with HIV - Research for an AIDS free generation. Geneva: World Health Organization; 2017.
298.
Collecting and reporting of sex- and age-disaggregated data on adolescents at the sub-national level New York City: UNICEF; 2016.
299.
United Nations General Assembly. United Nations Convention on the Rights of the Child. United Nations resolution A/Res/44/251989 of 20 November 1989.
300.
Global concensus statement: meaningful adolescent and youth engagement. Geneva: World Health Organization; 2020.
301.
Global Network of Young People living with HIV (Y+ Global). A guideline for organisations on the meaningful and ethical engagement of young people living with HIV in the HIV response. 2022.
302.
Adolescent friendly health services for adolescents living with HIV: from theory to practice, December 2019: a technical brief. Geneva: World Health Organization; 2019.
303.
World Health Organization, Joint United Nations Programme on HIV/AIDS. Global standards for quality health-care services for adolescents: a guide to implement a standards-driven approach to improve the quality of health-care services for adolescents. Geneva: World Health Organization; 2015.
304.
Conner B. “First, do no harm”: legal guidelines for health programmes affecting adolescents aged 10–17 who sell sex or inject drugs. J Int AIDS Soc. 2015;18:19437. [PMC free article: PMC4344536] [PubMed: 25724508]
305.
O’Farrell M, Corcoran P, Davoren MP. Examining LGBTI+ inclusive sexual health education from the perspective of both youth and facilitators: a systematic review. BMJ open. 2021;11(9):e047856. [PMC free article: PMC8413959] [PubMed: 34475162]
306.
What They Don’t Tell You in Sex Ed! – a resource for transgender and gender diverse communities on sexual and reproductive health. Asia Pacific Transgender Network (APTN); 2021.
307.
International technical and programmatic guidance on out-of-school comprehensive sexuality education (CSE). Geneva: World Health Organization; 2020. [PMC free article: PMC10431723] [PubMed: 37577783]
308.
READY to Care: improving health services for young people living with HIV. Global Network of Young People Living with HIV; 2019.
309.
Young key populations programming guidelines: inspiration for a new era of SRHR and HIV programming for young key populations in Asia-Pacific. Youth LEAD; 2021.
310.
Guidelines for healthcare providers on trans-competent healthcare services for transgender patients. Asia Pacific Transgender Network (APTN); 2020.
311.
Mark D, Lovich R, Walker D, Burdock T, Ronan A, Ameyan W, et al. Providing peer support for adolescents and young people living with HIV. Geneva: World Health Organization; 2019. Contract No. WHO/CDS/HIV/19.27.
312.
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021. Report No. 9240031596. [PubMed: 34370423]
313.
Looking out for adolescents and youth from key populations. UNICEF East Asia & Pacific; 2019.
314.
United Nations General Assembly. United Nations guidelines for the alternative care of children. United Nations resolution A/Res/64/142 of 2010.
315.
School-based violence prevention: a practical handbook. Geneva: World Health Organization; 2019.
316.
INSPIRE handbook: Action for implementing the seven strategies for ending violence against children. Geneva: World Health Organization; 2019.
317.
Jones T, Cornu C, Liu Y. Bringing it out in the open: monitoring school violence based on sexual orientation, gender identity or gender expression in national and international surveys. 2019.
318.
Embrace diversity and protect trans and gender diverse children and adolescents [press release]. UN Human Rights Office; 16 May 2017.
319.
Caring for women subjected to violence: a WHO curriculum for training health-care providers. Geneva: World Health Organization; 2019.
320.
Responding to children and adolescents who have been sexually abused. Geneva: World Health Organization; 2017. [PubMed: 29630189]
321.
Reproductive rights and human rights: a handbook for national human rights institutions Geneva: Office of High Commissioner on Human Rights; 2014.
322.
Family planning for adolescents and women at high risk for HIV. Geneva: World Health Organization; 2021.
323.
Actions for improved clinical and prevention services and choices: preventing HIV and other sexually transmitted infections among women and girls using contraceptive services in contexts with high HIV incidence. Geneva: World Health Organization; 2020.
324.
Laurenzi CA, du Toit S, Ameyan W, Melendez-Torres G, Kara T, Brand A, et al. Psychosocial interventions for improving engagement in care and health and behavioural outcomes for adolescents and young people living with HIV: a systematic review and meta-analysis. J Int AIDS Soc. 2021;24(8):e25741. [PMC free article: PMC8327356] [PubMed: 34338417]
325.
WHO guideline on school health services. Geneva: World Health Organization; 2021. [PMC free article: PMC571761] [PubMed: 34255443]
326.
Making every school a health-promoting school – implementation guidance. Geneva: World Health Organization; 2021.
327.
The right to housing of LGBT youth: an urgent task in the SDG agenda setting [press release]. Geneva: United Nations Human Rights Council; 2019.
328.
Free and equal: LGBTIQ+ Youth Homelessness. Fact sheet. Office of High Commissioner on Human Rights; 2020.
329.
Food systems for children and adolescents: working together to secure nutritious diets. New York: UNICEF; 2019.
330.
Carducci B, Oh C, Roth DE, Neufeld LM, Frongillo EA, L’Abbe MR, et al. Gaps and priorities in assessment of food environments for children and adolescents in low-and middle-income countries. Nature Food. 2021;2(6):396–403. [PubMed: 37118231]
331.
Transitions from school to work. New York: UNICEF; 2019.
332.
Recommended population size estimates of men who have sex with men. Geneva: World Health Organization; 2020.
333.
World Health Organization, Joint United Nations Programme on HIV/AIDS. Recommended population size estimates of men who have sex with men. Geneva: World Health Organization; 2020.
334.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343. [PMC free article: PMC3196245] [PubMed: 22008217]
335.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. [PMC free article: PMC5062054] [PubMed: 27733354]
336.
Desrosiers A, Levy M, Dright A, Zumer M, Jallah N, Kuo I, et al. A randomized controlled pilot study of a culturally-tailored counseling intervention to increase uptake of HIV pre-exposure prophylaxis among young black men who have sex with men in Washington, DC. AIDS Behav. 2019;23(1):105–15. [PMC free article: PMC6344254] [PubMed: 30171452]
337.
DiClemente RJ, Davis TL, Swartzendruber A, Fasula AM, Boyce L, Gelaude D, et al. Efficacy of an HIV/STI sexual risk-reduction intervention for African American adolescent girls in juvenile detention centers: a randomized controlled trial. Women Health. 2014;54(8):726–49. [PMC free article: PMC4224621] [PubMed: 25190056]
338.
L’Engle KL, Mwarogo P, Kingola N, Sinkele W, Weiner DH. A randomized controlled trial of a brief intervention to reduce alcohol use among female sex workers in Mombasa, Kenya. J Acquir Immune Defic Syndr. 2014;67(4):446–53. [PubMed: 25197826]
339.
Hao C, Huan X, Yan H, Yang H, Guan W, Xu X, et al. A randomized controlled trial to evaluate the relative efficacy of enhanced versus standard voluntary counseling and testing on promoting condom use among men who have sex with men in China. AIDS Behav. 2012;16(5):1138–47. [PubMed: 22298340]
340.
El-Bassel N, Gilbert L, Wu E, Witte SS, Chang M, Hill J, et al. Couple-based HIV prevention for low-income drug users from New York City: a randomized controlled trial to reduce dual risks. J Acquir Immune Defic Syndr (1999). 2011;58(2):198. [PMC free article: PMC5870871] [PubMed: 21725249]
341.
El-Bassel N, Gilbert L, Terlikbayeva A, Beyrer C, Wu E, Chang M, et al. Effects of a couple-based intervention to reduce risks for HIV, HCV, and STIs among drug-involved heterosexual couples in Kazakhstan: a randomized controlled trial. J Acquir Immune Defic Syndr (1999). 2014;67(2):196. [PMC free article: PMC4162759] [PubMed: 24991973]
342.
El-Bassel N, Gilbert L, Goddard-Eckrich D, Chang M, Wu E, Hunt T, et al. Efficacy of a group-based multimedia HIV prevention intervention for drug-involved women under community supervision: Project WORTH. PloS One. 2014;9(11):e111528. [PMC free article: PMC4221040] [PubMed: 25372149]
343.
Strathdee SA, Abramovitz D, Lozada R, Martinez G, Rangel MG, Vera A, et al. Reductions in HIV/STI incidence and sharing of injection equipment among female sex workers who inject drugs: results from a randomized controlled trial. PloS One. 2013;8(6):e65812. [PMC free article: PMC3681783] [PubMed: 23785451]
344.
Eaton LA, Kalichman SC, Kalichman MO, Driffin DD, Baldwin R, Zohren L, et al. Randomised controlled trial of a sexual risk reduction intervention for STI prevention among men who have sex with men in the USA. Sex Transm Infect. 2018;94(1):40–5. [PubMed: 28404766]
345.
Johnson A, Macgowan R, Eldridge G, Morrow K, Sosman J, Zack B, et al. Cost and threshold analysis of an HIV/STI/hepatitis prevention intervention for young men leaving prison: Project START. AIDS Behav. 2013;17(8):2676–84. [PubMed: 22124581]
346.
Burgos JL, Patterson TL, Graff-Zivin JS, Kahn JG, Rangel MG, Lozada MR, et al. Cost-effectiveness of combined sexual and injection risk reduction interventions among female sex workers who inject drugs in two very distinct Mexican border cities. PloS One. 2016;11(2):e0147719. [PMC free article: PMC4758635] [PubMed: 26890001]
347.
Stephenson R, Todd K, Kahle E, Sullivan SP, Miller-Perusse M, Sharma A, et al. Project Moxie: results of a feasibility study of a telehealth intervention to increase HIV testing among binary and nonbinary transgender youth. AIDS Behav. 2020;24(5):1517–30. [PMC free article: PMC7162704] [PubMed: 31760536]
348.
Moitra E, van den Berg JJ, Sowemimo-Coker G, Chau S, Nunn A, Chan PA. Open pilot trial of a brief motivational interviewing-based HIV pre-exposure prophylaxis intervention for men who have sex with men: preliminary effects, and evidence of feasibility and acceptability. AIDS Care. 2020 Mar;32(3):406–410. [PMC free article: PMC6875625] [PubMed: 31130000]
349.
United Nations Independent Expert on protection against violence and discrimination based on sexual orientation and gender identity. Report on conversion therapy. 2020.
350.
Velloza J, Kapogiannis B, Bekker L-G, Celum C, Hosek S, Delany-Moretlwe S, et al. Interventions to improve daily medication use among adolescents and young adults: what can we learn for youth pre-exposure prophylaxis services? AIDS. 2021;35(3):463. [PMC free article: PMC7855564] [PubMed: 33252486]
351.
Schreck B, Victorri-Vigneau C, Guerlais M, Laforgue E, Grall-Bronnec M. Slam practice: a review of the literature. European Addiction Research. 2021;27(3):161–78. [PubMed: 33279895]
352.
McCall H, Adams N, Mason D, Willis J. What is chemsex and why does it matter? BMJ. 2015 Nov 3;351:h5790. [PubMed: 26537832]
353.
Chemsex and harm reduction for gay men and other men who have sex with men: Briefing Note. London: Harm Reduction International; 2021.
354.
Maxwell S, Shahmanesh M, Gafos M. Chemsex behaviours among men who have sex with men: a systematic review of the literature. Int J Drug Policy. 2019;63:74–89. [PubMed: 30513473]
355.
APCOM. A qualitative scoping review of sexualized drug use (including Chemsex) of men who have sex with men and transgender women in Asia.2021.
356.
Pakianathan M, Whittaker W, Lee M, Avery J, Green S, Nathan B, et al. Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics. HIV Med. 2018;19(7):485–90. [PubMed: 29790254]
357.
Pakianathan M-WW, Lee MJ, Avery J,Green S, Nathan B,Hegazi A. Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics. HIV Med. 2018;19(7):485–90. [PubMed: 29790254]
358.
Tomkins A, George R, Kliner M. Sexualised drug taking among men who have sex with men: a systematic review. Perspect Public Health. 2019;139(1):23–33. [PubMed: 29846139]
359.
Bourne A, Reid D, Hickson F, Torres-Rueda S, Steinberg P, Weatherburn P. “Chemsex” and harm reduction need among gay men in South London. Int J Drug Policy. 2015;26(12):1171–6. [PubMed: 26298332]
360.
Herrijgers C, Poels K, Vandebosch H, Platteau T, van Lankveld J, Florence E. Harm reduction practices and needs in a Belgian chemsex context: findings from a qualitative study. Int J Environ Res Public Health. 2020;17(23):9081. [PMC free article: PMC7730975] [PubMed: 33291855]
361.
Tomkins A, Vivancos R, Ward C, Kliner M. How can those engaging in chemsex best be supported? An online survey to gain intelligence in Greater Manchester. Int J STD AIDS. 2018;29(2):128–34. [PubMed: 28691863]
362.
Bedi A, Sewell C, Fitzpatrick C. Peer-led education may be an effective harm reduction strategy for men who have sex with men engaging in ‘chemsex’. Int J STD AIDS. 2020;31(4):392–3. [PubMed: 32126948]
363.
Tan RKJ, Wong CM, Mark I, Chen C, Chan YY, Ibrahim MAB, et al. Chemsex among gay, bisexual, and other men who have sex with men in Singapore and the challenges ahead: a qualitative study. Int J Drug Policy. 2018;61:31–7. [PubMed: 30388567]
364.
Tang W, Wei C, Cao B, Wu D, Li KT, Lu H, et al. Crowdsourcing to expand HIV testing among men who have sex with men in China: a closed cohort stepped wedge cluster randomized controlled trial. PLoS medicine. 2018;15(8):1–19. [PMC free article: PMC6112627] [PubMed: 30153265]
365.
Zhu X, Zhang W, Operario D, Zhao Y, Shi A, Zhang Z, et al. Effects of a mobile health intervention to promote HIV self-testing with MSM in China: a randomized controlled trial. AIDS Behav. 2019;23(11):3129–39. [PMC free article: PMC6733671] [PubMed: 30852728]
366.
Lampkin D, Crawley A, Lopez TP, Mejia CM, Yuen W, Levy V. Reaching suburban men who have sex with men for STD and HIV services through online social networking outreach: a public health approach. J Acquir Immune Defic Syndr. 2016;72(1):73–8. [PubMed: 27097365]
367.
Horvath KJ, Lammert S, Danh T, Mitchell JW. The Feasibility, Acceptability and Preliminary Impact of Mobile Application to Increase Repeat HIV Testing Among Sexual Minority Men. AIDS Behav. 2020 Jun;24(6):1835–1850. [PubMed: 31823111]
368.
Horvath KJ, Lammert S, MacLehose RF, Danh T, Baker JV, Carrico AW. A pilot study of a mobile app to support HIV antiretroviral therapy adherence among men who have sex with men who use stimulants. AIDS Behav. 2019;23(11):3184–98. [PMC free article: PMC6803067] [PubMed: 31309348]
369.
Kuo I, Liu T, Patrick R, Trezza C, Bazerman L, Uhrig Castonguay BJ, et al. Use of an mHealth intervention to improve engagement in HIV community-based care among persons recently released from a correctional facility in Washington, DC: a pilot study. AIDS Behav. 2019;23(4):1016–31. [PMC free article: PMC6459706] [PubMed: 30627850]
370.
Songtaweesin WN, Kawichai S, Phanuphak N, Cressey TR, Wongharn P, Saisaengjan C, et al. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial. J Int AIDS Soc. 2020;23(5):e25564. [PMC free article: PMC7459171] [PubMed: 32869511]
371.
Young JD, Patel M, Badowski M, Mackesy-Amiti ME, Vaughn P, Shicker L, et al. Improved virologic suppression with HIV subspecialty care in a large prison system using telemedicine: an observational study with historical controls. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014;59(1):123–6. [PMC free article: PMC4305134] [PubMed: 24723283]
372.
Arayasirikul S, Turner C, Trujillo D, Le V, Wilson EC. Efficacy and impact of digital HIV care navigation in young people living with HIV in San Francisco, California: prospective study. JMIR mHealth and uHealth. 2020;8(5):e18597–e. [PMC free article: PMC7244993] [PubMed: 32383680]
373.
Brantley AD, Page KM, Zack B, Friedrich KR, Wendell D, Robinson WT, et al. Making the connection: using videoconferencing to increase linkage to care for incarcerated persons living with HIV post-release. AIDS Behav. 2019;23:32–40. [PubMed: 29680934]
374.
Bauermeister JA, Pingel ES, Jadwin-Cakmak L, Harper GW, Horvath K, Weiss G, et al. Acceptability and preliminary efficacy of a tailored online HIV/STI testing intervention for young men who have sex with men: the Get Connected! program. AIDS Behav. 2015;19(10):1860–74. [PMC free article: PMC4522230] [PubMed: 25638038]
375.
Young SD, Cumberland WG, Lee SJ, Jaganath D, Szekeres G, Coates T. Social networking technologies as an emerging tool for HIV prevention: a cluster randomized trial. Ann Int Med. 2013;159(5):318–24. [PMC free article: PMC3879120] [PubMed: 24026317]
376.
Ross C, Shaw S, Marshall S, Stephen S, Bailey K, Cole R, et al. Impact of a social media campaign targeting men who have sex with men during an outbreak of syphilis in Winnipeg, Canada. Can Commun Dis Rep. (Releve des maladies transmissibles au Canada). 2016;42(2):45–9. [PMC free article: PMC5864268] [PubMed: 29770003]
377.
Zhu X, Zhang W, Operario D, Zhao Y, Shi A, Zhang Z, et al. Effects of a mobile health intervention to promote HIV self-testing with MSM in China: a randomized controlled trial. AIDS Behav. 2019;23(11):3129–39. [PMC free article: PMC6733671] [PubMed: 30852728]
378.
Global strategy on digital health 2020–2025. Geneva: World Health Organization; 2021.
379.
Ross C, Shaw S, Marshall S, Stephen S, Bailey K, Cole R, et al. Update on STIs: impact of a social media campaign targeting men who have sex with men during an outbreak of syphilis in Winnipeg, Canada. Canada Commun Dis Rep. 2016;42(2):45. [PMC free article: PMC5864268] [PubMed: 29770003]
380.
FHI360. Going Online: a budgetting and programming aid for virtual HIV interventions. Durham (NC): FHI360; 2021.
381.
Alarcón Gutiérrez M, Fernández Quevedo M, Martín Valle S, Jacques-Aviñó C, Díez David E, Caylà JA, et al. Acceptability and effectiveness of using mobile applications to promote HIV and other STI testing among men who have sex with men in Barcelona, Spain. Sex Transm Infect. 2018;94(6):443–8. [PubMed: 29626174]
382.
Ybarra M, Nyemara N, Mugisha F, Garofalo R. Opportunities to Harness Technology to Deliver HIV Prevention / Healthy Sexuality Programming to Sexual and Gender Minority Adults Living in East Africa. AIDS Behav. 2021 Apr;25(4):1120–1128. [PMC free article: PMC10184554] [PubMed: 33123824]
383.
Cao B, Zhao P, Bien C, Pan S, Tang W, Watson J, et al. Linking young men who have sex with men (YMSM) to STI physicians: a nationwide cross-sectional survey in China. BMC Infect Dis. 2018;18(1):1–8. [PMC free article: PMC5960109] [PubMed: 29776395]
384.
Ventuneac A, John SA, Whitfield THF, Mustanski B, Parsons JT. Preferences for sexual health smartphone app features among gay and bisexual men. AIDS Behav. 2018;22(10):3384–94. [PMC free article: PMC6148366] [PubMed: 29948335]
385.
Fontenot HB, Rosenberger JG, McNair KT, Mayer KH, Zimet G. Perspectives and preferences for a mobile health tool designed to facilitate HPV vaccination among young men who have sex with men. Hum Vaccin Immunother. 2019;15(7–8):1815–23. [PMC free article: PMC6746522] [PubMed: 30625049]
386.
Balán IC, Lopez-Rios J, Nayak S, Lentz C, Arumugam S, Kutner B, et al. SMARTtest: a smartphone app to facilitate HIV and syphilis self- and partner-testing, interpretation of results, and linkage to care. AIDS Behav. 2019;24(5):1560–73. [PMC free article: PMC7162728] [PubMed: 31679075]
387.
Brennan DJ, Souleymanov R, Lachowsky N, Betancourt G, Pugh D, McEwen O. Providing online-based sexual health outreach to gay, bisexual, and queer men in Ontario, Canada: qualitative interviews with multisectoral frontline service providers and managers. AIDS Patient Care STDs. 2018;32(7):282–7. [PubMed: 29897787]
388.
Fantus S, Souleymanov R, Lachowsky NJ, Brennan DJ. The emergence of ethical issues in the provision of online sexual health outreach for gay, bisexual, two-spirit and other men who have sex with men: perspectives of online outreach workers. BMC Med Ethics. 2017;18(1):59–70. [PMC free article: PMC5670555] [PubMed: 29100520]
389.
Recommendations on digital interventions for health system strengthening. Geneva: World Health Organization; 2019. [PubMed: 31162915]
390.
FHI360. A vision for going online to accelerate the impact of HIV programs. Washington DC, USA: FHI360; 2019.
391.
Cunningham WE, Weiss RE, Nakazono T, Malek MA, Shoptaw SJ, Ettner SL, et al. Effectiveness of a peer navigation intervention to sustain viral suppression among HIV-positive men and transgender women released from jail: the LINK LA randomized clinical trial. JAMA Intern Med. 2018;178(4):542–53. [PMC free article: PMC5885257] [PubMed: 29532059]
392.
Reback CJ, Kisler KA, Fletcher JB. A novel adaptation of peer health navigation and contingency management for advancement along the HIV care continuum among transgender women of color. AIDS Behav. 2021;25(1):40–51. [PMC free article: PMC6904539] [PubMed: 31187355]
393.
Kerrigan D, Barrington C, Donastorg Y, Perez M, Galai N. Abriendo Puertas: feasibility and effectiveness a multi-level intervention to improve HIV outcomes among female sex workers living with HIV in the Dominican Republic. AIDS Behav. 2016;20(9):1919–27. [PubMed: 27016102]
394.
Micheni M, Kombo BK, Secor A, Simoni JM, Operario D, van der Elst EM, et al. Health provider views on improving antiretroviral therapy adherence among men who have sex with men in coastal Kenya. AIDS Patient Care STDs. 2017;31(3):113–21. [PMC free article: PMC5359680] [PubMed: 28282249]
395.
Pitpitan EV, Mittal ML, Smith LR. Perceived need and acceptability of a community-based peer navigator model to engage key populations in HIV care in Tijuana, Mexico. J Int Assoc Provid AIDS Care (JIAPAC). 2020;19:2325958220919276. [PMC free article: PMC7175050] [PubMed: 32314646]
396.
Guidelines for the screening, care and treatment of persons with chronic Hepatitis C Infection. Geneva: World Health Organization; 2016. [PubMed: 27227200]
397.
Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109–20. [PMC free article: PMC3972017] [PubMed: 23908124]
398.
Hellard M, Sacks-Davis R, Doyle J. Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks. J Epidemiol Community Health. 2016;70(12):1151–4. [PubMed: 27343304]
399.
Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25(3):220–7. [PMC free article: PMC5841922] [PubMed: 29316030]
400.
EASL recommendations on treatment of hepatitis C: final update of the series(☆). J Hepatol. 2020;73(5):1170–218. [PubMed: 32956768]
401.
Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, et al. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PloS One. 2019;14(6):e0217964. [PMC free article: PMC6553784] [PubMed: 31170246]
402.
Castry M, Cousien A, Supervie V, Velter A, Ghosn J, Paltiel AD, Yazdanpanah Y, Deuffic-Burban S. Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach. Gut. 2020 Oct 27:gutjnl-2020-321744. [PubMed: 33109688]
403.
Castry M, Cousien A, Supervie V, Velter A, Ghosn J, Paltiel AD, et al. Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach. Gut. 2021;70(8):1561–9. [PubMed: 33109688]
404.
Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, et al. Short-duration pan-genotypic therapy with glecaprevir/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection. Hepatology. 2020;72(1):7–18. [PubMed: 31652357]
405.
Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170–218. [PubMed: 32956768]
406.
Ghany MG, Morgan TR, panel AIhCg. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America: Recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721. [PMC free article: PMC9710295] [PubMed: 31816111]
407.
Gómez-Ayerbe C, Palacios R, Ríos MJ, Téllez F, Sayago C, Martín-Aspas A, et al. Acute hepatitis C virus infection and direct-acting antiviral drugs: perfect combination to eliminate the epidemic? Int J STD & AIDS. 2021:09564624211033756. [PubMed: 34293985]
408.
Boesecke C, Nelson M, Ingiliz P, Lutz T, Scholten S, Cordes C, et al., editors. Can’t buy me love? Obstacles to microelimination of acute HCV coinfection in Europe. In: Twenty-sixth conference on retroviruses and opportunistic infections; 2019.
409.
Chromy D, Mandorfer M, Bucsics T, Schwabl P, Scheiner B, Schmidbauer C, et al. High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. United Eur Gastroenterol J. 2019;7(4):507–16. [PMC free article: PMC6488804] [PubMed: 31065368]
410.
Cannon L, Dhillon R, A T, Teo S, Garner A, Ward C, et al. Hepatitis C infection and treatment outcomes in the DAA era. HIV Med. 2020;21:51.
411.
Cotte L, Hocqueloux L, Lefebvre M, Pradat P, Bani-Sadr F, Huleux T, Poizot-Martin I, Pugliese P, Rey D, Cabié A; Dat’AIDS Study Group. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018. Clin Infect Dis. 2021 Nov 2;73(9):e3266–e3274. [PubMed: 33400777]
412.
Garvey LJ, Cooke GS, Smith C, Stingone C, Ghosh I, Dakshina S, et al. Decline in hepatitis C virus (HCV) incidence in men who have sex with men living with human immunodeficiency virus: progress to HCV microelimination in the United Kingdom? Clin Infect Dis. 2020;72(2):233–8. [PMC free article: PMC7840101] [PubMed: 32211763]
413.
Girometti N, Devitt E, Phillips J, Nelson M, Whitlock G. High rates of unprotected anal sex and use of generic direct-acting antivirals in a cohort of MSM with acute HCV infection. J Viral Hepat. 2019;26(6):627–34. [PubMed: 30661272]
414.
Huang MH, Chang SY, Liu CH, Cheng A, Su LH, Liu WC, et al. HCV reinfections after viral clearance among HIV-positive patients with recent HCV infection in Taiwan. Liver Int. 2019;39(10):1860–7. [PubMed: 31343813]
415.
Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, et al. Ledipasvir/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals. Clin Infect Dis. 2019;69(3):514–22. [PMC free article: PMC6637278] [PubMed: 31220220]
416.
Braun DL, Hampel B, Ledergerber B, Grube C, Nguyen H, Künzler-Heule P, et al. A treatment-as-prevention trial to eliminate hepatitis C among men who have sex with men living with human immunodeficiency virus (HIV) in the Swiss HIV cohort study. Clin Infect Dis. 2021;73(7):e2194–e202. [PubMed: 32761122]
417.
Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, Dore GJ; REACT study group; Protocol Steering Committee; Coordinating Centre; Site Principal Investigators. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol. 2021 Oct;75(4):829–839. [PMC free article: PMC9831671] [PubMed: 34023350]
418.
Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, et al. Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs. 2019;39(12):2244–60. [PubMed: 31125496]
419.
Palaniswami PM, El Sayed A, Asriel B, Carollo JR, Fierer DS, editors. Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men. Open Forum Infect Dis. 2018; Oxford University Press US. [PMC free article: PMC6189631] [PubMed: 30349848]
420.
Bethea ED, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and costeffectiveness analysis. Hepatology (Baltimore, Md). 2018;67(3):837–46. [PMC free article: PMC5826841] [PubMed: 29059461]
421.
Liu Y, Zhang H, Zhang L, Zou X, Ling L. Economic evaluation of hepatitis C treatment extension to acute infection and early-stage fibrosis among patients who inject drugs in developing countries: a case of China. Int J Environm Res Public Health. 2020;17(3). [PMC free article: PMC7037788] [PubMed: 32012839]
422.
Mukherjee S, Colby D, Ramautarsing R, Popping S, Sriplienchan S, Chinbunchorn T, et al. Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: a cost effectiveness modelling study. J Virus Erad. 2021;7(2):100042. [PMC free article: PMC8184647] [PubMed: 34141441]
423.
Popping S, Hullegie SJ, Boerekamps A, Rijnders BJA, de Knegt RJ, Rockstroh JK, et al. Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS One. 2019;14(1):e0210179. [PMC free article: PMC6328146] [PubMed: 30629662]
424.
Hepatitis 2021. World Health Organization; 2021 (https://www​.who.int/health-topics​/hepatitis#tab=tab_1, accessed 14 March 2022).
425.
Unemo M, Jensen JS. Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nat Rev Urol. 2017;14(3):139–52. [PubMed: 28072403]
426.
Cristillo AD, Bristow CC, Torrone E, Dillon JA, Kirkcaldy RD, Dong H, et al. Antimicrobial resistance in Neisseria Gonorrhoeae: proceedings of the STAR sexually transmitted infection-clinical trial group programmatic meeting. Sex Transm Dis. 2019;46(3):e18–e25. [PMC free article: PMC6370498] [PubMed: 30363025]
427.
Barbee LA, Dombrowski JC, Kerani R, Golden MR. Effect of nucleic acid amplification testing on detection of extragenital gonorrhea and chlamydial infections in men who have sex with men sexually transmitted disease clinic patients. Sex Transm Dis. 2014;41(3):168–72. [PubMed: 24521722]
428.
van Liere GA, van Rooijen MS, Hoebe CJ, Heijman T, de Vries HJ, Dukers-Muijrers NH. Prevalence of and factors associated with rectal-only chlamydia and gonorrhoea in women and in men who have sex with men. PLoS One. 2015;10(10):e0140297. [PMC free article: PMC4626043] [PubMed: 26513479]
429.
Gunn RA, O’Brien CJ, Lee MA, Gilchick RA. Gonorrhea screening among men who have sex with men: value of multiple anatomic site testing, San Diego, California, 1997–2003. Sex Transm Dis. 2008;35(10):845–8. [PubMed: 18607315]
430.
Wi TE, Ndowa FJ, Ferreyra C, Kelly-Cirino C, Taylor MM, Toskin I, et al. Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward. J Int AIDS Soc. 2019;22(S6):e25343. [PMC free article: PMC6715950] [PubMed: 31468679]
431.
Aboud L, Xu Y, Chow EP, Wi T, Baggaley R, Mello MB, et al. Diagnostic accuracy of pooling urine, anorectal, and orooropharyngeal specimens for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae: a systematic review and meta-analysis. BMC Med. 2021;19(1):1–11. [PMC free article: PMC8614052] [PubMed: 34819068]
432.
Thammajaruk N, Promthong S, Posita P, Chumseng S, Nampaisan O, Srivachiraroj P, et al. Pooled oropharyngeal, rectal and urine samples for the point-of-care detection of Chlamydia trachomatis and Neisseria gonorrhoeae by lay-providers in key population-led health services in Thailand. J Int Aids Soc. 2020;23:115–6.
433.
Sultan B, White JA, Fish R, Carrick G, Brima N, Copas A, et al. The “3 in 1” study: pooling self-taken oropharyngeal, urethral, and rectal samples into a single sample for analysis for detection of Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men. J Clin Microbiol. 2016;54(3):650–6. [PMC free article: PMC4767962] [PubMed: 26719439]
434.
Dean JA, Bell SFE, Coffey L, Debattista J, Badman S, Redmond AM, et al. Improved sensitivity from pooled urine, oropharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near point of care. Sex Transm Infect. 2020;13:13. [PubMed: 33188137]
435.
Badman SG, Bell SFE, Dean JA, Lemoire J, Coffey L, Debattista J, et al. Reduced sensitivity from pooled urine, oropharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near the point of care. Sex Health. 2020;17(1):15–21. [PubMed: 31945307]
436.
Verougstraete N, Verbeke V, De Canniere AS, Simons C, Padalko E, Coorevits L. To pool or not to pool? Screening of Chlamydia trachomatis and Neisseria gonorrhoeae in female sex workers: pooled versus single-site testing. Sex Transm Infect. 2020;96(6):417–21. [PubMed: 32404400]
437.
De Baetselier I, Vuylsteke B, Yaya I, Dagnra A, Diande S, Mensah E, et al. To pool or not to pool samples for sexually transmitted infections detection in men who have sex with men? An evaluation of a new pooling method using the genexpert instrument in West Africa. Sex Transm Dis. 2020;47(8):556–61. [PubMed: 32355106]
438.
Wilson JD, Wallace HE, Loftus-Keeling M, Ward H, Davies B, Vargas-Palacios A, et al. Swab-yourself trial with economic monitoring and testing for infections collectively (SYSTEMATIC): Part 2. A diagnostic accuracy, and cost-effectiveness, study comparing rectal, oropharyngeal and urogenital samples analysed individually, versus as a pooled specimen, for the diagnosis of gonorrhoea and chlamydia. Clin Infect Dis. 2020;12:12. [PubMed: 33044490]
439.
Chernesky M, Jang D, Martin I, Arias M, Shah A, Smieja M, et al. Mycoplasma genitalium, Chlamydia trachomatis, and Neisseria gonorrhoeae detected with aptima assays performed on self-obtained vaginal swabs and urine collected at home and in a clinic. Sex Transm Dis. 2019;46(9):e87–e9. [PubMed: 31415336]
440.
Speers DJ, Chua IJ, Manuel J, Marshall L. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis from pooled rectal, oropharyngeal and urine specimens in men who have sex with men. Sex Transm Infect. 2018;94(4):293–7. [PubMed: 29066627]
441.
Shaw J, Saunders JM, Hughes G. Attitudes to, and experience of, pooled sampling for sexually transmitted infection testing: a web-based survey of English sexual health services. Int J STD AIDS. 2018;29(6):547–51. [PubMed: 29157170]
442.
De Baetselier I, Osbak KK, Smet H, Kenyon CR, Crucitti T. Take three, test one: a cross-sectional study to evaluate the molecular detection of Chlamydia trachomatis and Neisseria gonorrhoeae in pooled oropharyngeal, anorectal and urine samples versus single-site testing among men who have sex with men in Belgium. Acta Clinica Belgica. 2020;75(2):91–5. [PubMed: 30415606]
443.
Guidelines for the Treatment of Chlamydia trachomatis. Geneva: World Health Organization; 2016. [PubMed: 27559553]
444.
Guidelines for the treatment of Neisseria gonorrhoeae. Geneva: World Health Organization; 2016. [PubMed: 27512795]
© World Health Organization 2022.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Bookshelf ID: NBK586593

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...